Prevalence of anticipatory nausea and emesis in cancer chemotherapy patients.
The prevalence of anticipatory nausea (AN) and anticipatory emesis (AE) in 71 cancer chemotherapy outpatients was measured by a self-report questionnaire. An 18.3% prevalence rate was found, with a mean onset of 5.12 hr prior to treatment. AN/AE most typically occurred at home or while traveling to the clinic and those who experienced it also reported a significantly higher frequency of posttreatment nausea, vomiting, constipation, and dry and itching skin.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000523:psychology; D012718:Set, Psychology; D014839:Vomiting / Q000139:chemically induced* / Q000523:psychology
D000970:Antineoplastic Agents